# This SDS packet was issued with item: 078677147

The safety data sheets (SDS) in this packet apply to the individual products listed below. Please refer to invoice for specific item number(s).

078677139 078677154 078677162



Revision date: 28-Jan-2014

Version: 3.0

### 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

**Product Identifier** 

Material Name: Simplicef (Cefpodoxime Proxetil) Tablets - 100 and 200 mg

Trade Name: Synonyms: Chemical Family: SIMPLICEF Cefpodoxime Proxetil Tablets Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against Intended Use: Veterinary product used as antibiotic agent

Details of the Supplier of the Safety Data Sheet

Zoetis Inc. 100 Campus Drive, P.O. Box 651 Florham Park, New Jersey 07932 (USA) Rocky Mountain Poison Control Center Phone: 1-866-531-8896 Product Support/Technical Services Phone: 1-800-366-5288

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300 Contact E-Mail: VMIPSrecords@zoetis.com Zoetis Belgium S.A. Mercuriusstraat 20 1930 Zaventem Belgium

Emergency telephone number: International CHEMTREC (24 hours): +1-703-527-3887

# 2. HAZARDS IDENTIFICATION

Appearance: Orange tablets Classification of the Substance or Mixture GHS - Classification

> Respiratory Sensitization: Category 1 Skin Sensitization: Category 1

### EU Classification:

EU Indication of danger: Xn - Harmful Irritant; (Xi) EU Risk Phrases:

R42/43 - May cause sensitization by inhalation and skin contact.

#### Label Elements

Signal Word:DangerHazard Statements:H334 - May cause allergy or asthma symptoms or breathing difficulties if inhaled<br/>H317 - May cause an allergic skin reaction

Material Name: Simplicef (Cefpodoxime Proxetil) Tablets - 100 and 200 mg Revision date: 28-Jan-2014

Version: 3.0

Precautionary Statements:	<ul> <li>P261 - Avoid breathing dust/fume/gas/mist/vapors/spray</li> <li>P284 - Wear respiratory protection</li> <li>P272 - Contaminated work clothing should not be allowed out of the workplace</li> <li>P280 - Wear protective gloves/protective clothing/eye protection/face protection</li> <li>P304 + P340 - IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing</li> <li>P342 + P311 - If experiencing respiratory symptoms: Call a POISON CENTRE or doctor/physician</li> <li>P302+ P352 - IF ON SKIN: Wash with plenty of soap and water</li> <li>P333 + P313 - If skin irritation or rash occurs: Get medical advice/attention</li> <li>P362 - Take off contaminated clothing and wash before reuse</li> <li>P501 - Dispose of contents/container in accordance with all local and national regulations</li> </ul>	
Other Hazards Short Term: Known Clinical Effects:	May cause stomach irritation, diarrhea, nausea, or vomiting. Individuals who are sensiti beta lactam antibiotics, both penicillins and cephalosporins, may experience contact or systemic hypersensitivity and anaphylaxis upon exposure to this drug. Hypersensitivity reactions may also occur in susceptible individuals. May cause effects to those generally seen in clinical use of antibiotics including gastrointestinal irritation, w transient diarrhea, nausea, and abdominal pain. Pseudomembranous colitis (manifeste watery diarrhea, urge to defecate, abdominal cramps, low-grade fever, bloody stools, ar	
Australian Hazard Classification (NOHSC):	abdominal pain) may also occur. Hazardous Substance. Non-Dangerous Goods.	
Note:	This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.	

# **3. COMPOSITION/INFORMATION ON INGREDIENTS**

#### Hazardous

Ingredient	CAS Number	EU	EU Classification	GHS	%
		EINECS/ELINCS		Classification	
		List			
Cefpodoxime Proxetil	87239-81-4	Not Listed	Xn;R42/43	Resp.Sens.1,H334	30.3
				Skin Sens. 1,H317	
Sodium Lauryl Sulfate	151-21-3	205-788-1	Not Listed	Not Listed	*
Magnesium Stearate	557-04-0	209-150-3	Not Listed	Not Listed	*

### **Additional Information:**

\* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

### For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

### **4. FIRST AID MEASURES**

Description of First Aid Measures Eye Contact:	Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.
Skin Contact:	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
Ingestion:	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.
Inhalation:	Remove to fresh air and keep patient at rest. Seek medical attention immediately.
Most Important Symptoms and Effect Symptoms and Effects of Exposure: Medical Conditions Aggravated by Exposure:	cts, Both Acute and Delayed For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information. None known

Indication of the Immediate Medical Attention and Special Treatment Needed Notes to Physician: None

### **5. FIRE-FIGHTING MEASURES**

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

#### Special Hazards Arising from the Substance or Mixture

```
Hazardous CombustionFormation of toxic gases is possible during heating or fire.Products:
```

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

#### **Advice for Fire-Fighters**

Wear approved positive pressure, self-contained breathing apparatus and full protective turn out gear. Dike and collect water used to fight fire.

### 6. ACCIDENTAL RELEASE MEASURES

#### Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

#### **Environmental Precautions**

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

### Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting:	Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.
Additional Consideration for Large Spills:	Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

Material Name: Simplicef (Cefpodoxime Proxetil) Tablets - 100 and 200 mg Revision date: 28-Jan-2014 Page 4 of 9

Version: 3.0

### 7. HANDLING AND STORAGE

#### **Precautions for Safe Handling**

If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls. Keep away from heat, sparks, and flame.

#### Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions:Store as directed by product packaging.Specific end use(s):No data available

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

#### **Control Parameters**

Refer to available public information for specific member state Occupational Exposure Limits.

Cefpodoxime Proxetil		
Zoetis OEL TWA 8-hr	100µg/m³ Sensitizer	
Magnesium Stearate		
ACGIH Threshold Limit Value	( <b>TWA</b> ) 10 mg/m <sup>3</sup>	
Lithuania OEL - TWA	5 mg/m <sup>3</sup>	
Sweden OEL - TWAs	5 mg/m <sup>3</sup>	
Exposure Controls		
Engineering Controls:	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes.	
Personal Protective	Refer to applicable national standards and regulations in the selection and use of personal	
Equipment:	protective equipment (PPE).	
Hands:	Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.	
Eyes:	Wear safety glasses or goggles if eye contact is possible.	
Skin:	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.	
Respiratory protection:	If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.	

### 9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	
Odor:	
Molecular Formula:	
Solvent Solubility: Water Solubility:	
<u>юЦ</u> ,	

Dhusiaal State

Tablets No data available. Mixture No data available Color: Odor Threshold: Molecular Weight: Orange No data available. Mixture

Water Solubility:No data availablepH:No data available.Melting/Freezing Point (°C):No data available.Boiling Point (°C):No data available.

Material Name: Simplicef (Cefpodoxime Proxetil) Tablets - 100 and 200 mg Revision date: 28-Jan-2014

#### Page 5 of 9

Version: 3.0

### 9. PHYSICAL AND CHEMICAL PROPERTIES

 Partition Coefficient: (Method, pH, Endpoint, Value)

 No data available

 Decomposition Temperature (°C):

No data available.

Evaporation Rate (Gram/s):	No data available
Vapor Pressure (kPa):	No data available
Vapor Density (g/ml):	No data available
Relative Density:	No data available
Viscosity:	No data available

Flammablity:

Autoignition Temperature (Solid) (°C): Flammability (Solids): Flash Point (Liquid) (°C): Upper Explosive Limits (Liquid) (% by Vol.): Lower Explosive Limits (Liquid) (% by Vol.): Polymerization: No data available Will not occur

### **10. STABILITY AND REACTIVITY**

Reactivity: Chemical Stability: Possibility of Hazardous Reactions Oxidizing Properties: Conditions to Avoid: Incompatible Materials: Hazardous Decomposition Products:

No data available Stable at normal conditions

No data available Fine particles (such as dust and mists) may fuel fires/explosions. As a precautionary measure, keep away from strong oxidizers No data available

### **11. TOXICOLOGICAL INFORMATION**

Information on Toxicological Effects General Information:

The information included in this section describes the potential hazards of the individual ingredients. Toxicological properties of the formulation have not been investigated.

### Acute Toxicity: (Species, Route, End Point, Dose)

#### **Cefpodoxime Proxetil**

MouseOralLD 50> 8000 mg/kgMouseSub-tenon injection (eye)LD 502535mg/kgMouseSubcutaneousLD 50> 10,000mg/kgRatIntravenousLD 50> 4000mg/kg

Lactose Monohydrate Rat Oral LD 50 29700 mg/kg

#### Sodium Lauryl Sulfate

 Rat
 Oral
 LD 50
 1288 mg/kg

 Rat
 Sub-tenon injection (eye)
 LD 50
 210mg/kg

 Acute Toxicity Comments:
 A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Material Name: Simplicef (Cefpodoxime Proxetil) Tablets - 100 and 200 mg Revision date: 28-Jan-2014 Page 6 of 9

Version: 3.0

# **11. TOXICOLOGICAL INFORMATION**

Irritation / Sensitization: (Study Type, Species, Severity)

### **Cefpodoxime Proxetil**

Eye IrritationRabbitMinimalSkin IrritationRabbitNo effect

### Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

#### Magnesium Stearate

13 Week(s) Rat Oral 1092 g/kg LOAEL Liver

### Sodium Lauryl Sulfate

3 Day(s) Rat Oral 75 mg/kg LOAEL Liver, Blood

### Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

### **Cefpodoxime Proxetil**

>500 mg/kg/day **Reproductive & Fertility** Rat Oral NOAEL Fertility Fertility Reproductive & Fertility Rabbit Oral > 500 mg/kg/day NOAEL Embryo / Fetal Development Rat Oral 100 mg/kg/day NOAEL Not Teratogenic, Fetotoxicity Embryo / Fetal Development 30 mg/kg/day NOAEL Not Teratogenic, Fetotoxicity Rabbit Oral

### Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

### **Cefpodoxime Proxetil**

Bacterial Mutagenicity (Ames) Salmonella Negative Chromosome Aberration Negative Unscheduled DNA Synthesis Negative In Vivo Micronucleus Negative

### Lactose Monohydrate

In Vitro Bacterial Mutagenicity (Ames) Negative

#### Water

Bacterial Mutagenicity (Ames)NegativeIn Vivo Dominant Lethal AssayDrosophilaNegativeIn Vivo MicronucleusMouse RatNegative

Carcinogen Status:

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

Material Name: Simplicef (Cefpodoxime Proxetil) Tablets - 100 and 200 mg Revision date: 28-Jan-2014 Page 7 of 9

Version: 3.0

# **12. ECOLOGICAL INFORMATION**

Environmental Overview:	Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.
Toxicity:	No data available
Persistence and Degradability:	No data available
Bio-accumulative Potential:	No data available
Mobility in Soil:	No data available

# 13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods:

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

### 14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

### **15. REGULATORY INFORMATION**

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications WHMIS hazard class: Class D, Division 2, Subdivision A Class D, Division 2, Subdivision B



Material Name: Simplicef (Cefpodoxime Proxetil) Tablets - 100 and 200 mg Revision date: 28-Jan-2014

Page 8 of 9	•

Version: 3.0

### **15. REGULATORY INFORMATION**

Cefpodoxime Proxetil	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed
Sodium Lauryl Sulfate	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling	Schedule 6
for Drugs and Poisons:	
EU EINECS/ELINCS List	205-788-1
Magnesium Stearate	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	209-150-3

### **16. OTHER INFORMATION**

### Text of R phrases and GHS Classification abbreviations mentioned in Section 3

H317 - May cause an allergic skin reaction

H334 - May cause allergy or asthma symptoms or breathing difficulties if inhaled

Xn - Harmful Xi - Irritant

R42/43 - May cause sensitization by inhalation and skin contact.

Data Sources:	The data contained in this MSDS may have been gathered from confidential internal sources, raw material suppliers, or from the published literature.
Reasons for Revision:	Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 11 - Toxicology Information. Updated Section 15 - Regulatory Information.
Prepared by:	Toxicology and Hazard Communication

Zoetis Global Risk Management

Zoetis Inc. believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

### End of Safety Data Sheet

Material Name: Simplicef (Cefpodoxime Proxetil) Tablets - 100 and 200 mg Revision date: 28-Jan-2014

Page 9 of 9

Version: 3.0